COVENTRY, United Kingdom--(BUSINESS WIRE)--Bruker Daltonics announced today the establishment of a long-term collaborative programme for developing both applications and fundamental instrument technology in the area of extreme resolution mass spectrometry.

Building on over 14 years of experience in high performance mass spectrometry at the Department of Chemistry at Warwick, the University’s recent acquisition of both the new Bruker solariX™ 12 Tesla FTMS system and the maXis™ UHR-TOF system again puts the department at the forefront of technology for high performance mass spectrometry. At the core of the new instruments are dramatic improvements, up to an order of magnitude, in previous performance standards. These advances help address the University’s most challenging analyses including very complex mixtures in applications such as chemistry, medicinal discovery, protein interactions and petroleomics.

The collaboration is unusual in that it embraces not only topical applications innovation but also fundamental instrument development, the latter headed by Warwick Professor Peter O’Connor, who recently arrived from Boston University, and is one of the world’s most accomplished FTMS instrument development scientists. “We are very excited to be able to benefit from Peter’s ideas, and have arranged a technical fast-track for his developments to appear in our FTMS products,” commented Dr. Michael Schubert, Executive Vice President for R&D at Bruker Daltonics.

Professor Peter Sadler, Head of Chemistry at the University, whose research interests focus on metals in biology and medicine, the design and mechanism of action of metallodrugs, especially the role of proteins in metal-induced signal transduction said: “In my field state-of-the-art analysis of metal speciation holds the key to major breakthroughs in understanding both how metal ions control natural biological processes, and how metal complexes can be designed as novel therapeutic agents. Moreover, this new Bruker mass spec equipment, and the associated collaboration, will allow our newly established EPSRC Warwick Centre for Analytical Science to compete strongly at the forefront of the field.”

“We are delighted that Professors Sadler and O’Connor, who both have outstanding track records in the design and implementation of cutting-edge mass spectrometry, have chosen Bruker as a supplier and collaborative partner. It is especially gratifying to see real instrument development receiving such an energetic renewal in the UK,” commented Dr. Ian Sanders, Executive Vice President for Worldwide Sales and Marketing at Bruker Daltonics.

The solariX and maXis will be highlighted at the 18^th International Mass Spectrometry Conference (www.imsc-bremen-2009.de) in Bremen, Germany from August 30 to September 4, 2009. For more information on IMSC 2009 and related Bruker Daltonics activities, please visit www.bdal.com/imsc.

ABOUT BRUKER DALTONICS

For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR - News), please visit www.bdal.com and www.bruker.com.

A method for discovering entirely new career paths for existing clinical drugs is being exploited by start-up company Tangent Reprofiling Ltd., following a deal just signed between the company, PepTcell Limited, the University of Warwick and Warwick spin-out company a2sp Ltd.

The technique, developed at the University of Warwick, enables researchers to investigate potential new uses for drugs which are already approved for clinical use.

Tangent Reprofiling, set up as a subsidiary of the immunology company PepTcell, and based in High Wycombe, Buckinghamshire, has now acquired the intellectual property which will allow it to make use of the technique.

The idea of ‘reprofiling’ drugs is not unique to Tangent – perhaps the most famous example is the drug Viagra, which was originally developed to combat high blood pressure and angina. However this particular technique allows researchers to assess a wide landscape of current drugs in a cost and time efficient manner, using a combination of established chemical genomics techniques and proprietary chemistry.

Dr Suzanne Dilly, Tangent’s new CEO, explained, “Most drugs work by interacting with proteins in the body. By using the technology platform developed by a2sp Ltd, we can look for unexpected interactions between a drug and different proteins and then suggest potential new uses for that drug.

“One advantage of reprofiling drugs is that they have already gone through the rigorous tests required before a drug can be cleared for clinical use, a process which can take several years.”

Commonly used industrial dyes hold the key to advancing the new science of 'spintronics', say researchers working on a new a £2.5 million study.

Spintronics holds out the possibility of a range of future applications, such as quantum computing, which aims to deliver secure, low-power computers capable of processing much larger quantities of data than is currently possible. Scientists believe that sensitive new biosensors able to analyse blood or urine samples rapidly and accurately could also be developed as a result of this work.

The new Basic Technology grant awarded by the Engineering and Physical Sciences Research Council will support research into the magnetic properties of metal atoms found in industrial dyes such as Metal Phthalocyanine (MPc), a blue dye used in clothing. The team from the London Centre for Nanotechnology - a joint venture between Imperial College London and University College London - and the University of Warwick believes that finding ways to control and exploit these molecules will allow spintronics to be applied in new ways.